Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Artiva Biotherapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 40
- −8 vs. Q2 2025
- Shares held
- 18.2M
- −355.0K (−1.9%) vs. Q2 2025
- Total value
- $52.1M
- +$24.2M (+86.4%) vs. Q2 2025
- New holders
- 6
- 8 more added
- Sold out
- 14
- 16 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 72 | $391.6M |
| Q1 2026 | 40 | $108.4M |
| Q4 2025 | 34 | $72.7M |
| Q3 2025 | 40 | $52.1M |
| Q2 2025 | 48 | $27.9M |
| Q1 2025 | 53 | $62.8M |
| Q4 2024 | 57 | $213.2M |
| Q3 2024 | 49 | $319.4M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Artiva Biotherapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cloud Capital Management, LLC | 11 | $0 | 0.00% | +11 | New |
| EverSource Wealth Advisors, LLC | 159 | $456 | 0.00% | +159 | New |
| Mark Sheptoff Financial Planning, LLC | 400 | $1.15K | 0.00% | 00.0% | Unchanged |
| GF Fund Management Co. Ltd. | 510 | $1.46K | 0.00% | −93−15.4% | Reduced |
| Mirae Asset Global Investments Co., Ltd. | 944 | $2.71K | 0.00% | +3+0.3% | Added |
| Royal Bank of Canada | 840 | $3.00K | 0.00% | −280−25.0% | Reduced |
| Wells Fargo & Company | 1,700 | $4.88K | 0.00% | −364−17.6% | Reduced |
| JPMorgan Chase & Co | 4,002 | $11.5K | 0.00% | +3,137+362.7% | Added |
| China Universal Asset Management Co., Ltd. | 4,281 | $12.3K | 0.00% | −612−12.5% | Reduced |
| FMR LLC | 4,920 | $14.1K | 0.00% | −37,357−88.4% | Reduced |
| Russell Investments Group, Ltd. | 5,491 | $15.8K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 9,981 | $28.6K | 0.00% | −117−1.2% | Reduced |
| Barclays PLC | 12,696 | $36.4K | 0.00% | +10,790+566.1% | Added |
| Prelude Capital Management, LLC | 14,302 | $41.0K | 0.00% | +14,302 | New |
| Bank of America Corp | 16,145 | $46.3K | 0.00% | +11,190+225.8% | Added |
| Two Sigma Investments, LP | 20,364 | $58.4K | 0.00% | −1,007−4.7% | Reduced |
| UBS Group AG | 21,143 | $60.7K | 0.00% | +17,806+533.6% | Added |
| Qube Research & Technologies Ltd | 25,552 | $73.3K | 0.00% | −13,140−34.0% | Reduced |
| HRT Financial LP | 26,953 | $77.0K | 0.00% | −50,703−65.3% | Reduced |
| Bridgeway Capital Management, LLC | 35,000 | $100.5K | 0.00% | 00.0% | Unchanged |
| Landscape Capital Management, L.L.C. | 39,133 | $112.3K | 0.01% | +39,133 | New |
| Morgan Stanley | 42,829 | $122.9K | 0.00% | −3,418−7.4% | Reduced |
| XTX Topco Ltd | 47,973 | $137.7K | 0.01% | +47,973 | New |
| Goldman Sachs Group Inc | 49,777 | $142.9K | 0.00% | −68,226−57.8% | Reduced |
| State Street Corp | 59,824 | $171.7K | 0.00% | −3,050−4.9% | Reduced |
| Renaissance Technologies LLC | 79,147 | $227.2K | 0.00% | +79,147 | New |
| Alyeska Investment Group, L.P. | 100,000 | $287.0K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 105,573 | $303.0K | 0.00% | +102,006+2,859.7% | Added |
| Geode Capital Management, LLC | 110,896 | $318.5K | 0.00% | −48,145−30.3% | Reduced |
| BNP Paribas Arbitrage, SA | 118,547 | $340.2K | 0.00% | +117,733+14,463.5% | Added |
| Vanguard Group Inc | 159,118 | $456.7K | 0.00% | −73,854−31.7% | Reduced |
| Wellington Management Group LLP | 194,108 | $557.1K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 262,160 | $752.4K | 0.00% | −64,907−19.8% | Reduced |
| BlackRock, Inc. | 294,422 | $845.0K | 0.00% | −191,305−39.4% | Reduced |
| Franklin Resources Inc | 520,327 | $1.49M | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 798,397 | $2.29M | 0.00% | +644,658+419.3% | Added |
| venBio Partners LLC | 1,148,975 | $3.30M | 1.87% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,609,569 | $4.62M | 0.26% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 2,353,304 | $6.75M | 2.47% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 9,853,302 | $28.3M | 0.35% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 0 | $0 | 0.00% | −291,666−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −283,124−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −52,213−100.0% | Sold out |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −45,456−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −44,215−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −41,395−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −34,964−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −31,567−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −24,849−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −17,171−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −16,121−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −3,383−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −329−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |